(Q35751912)

10 August 2017

title

Novel Therapies in Development for Diabetic Macular Edema (English)

1 reference

10 August 2017

Aniruddha Agarwal

1

1 reference

10 August 2017

Rubbia Afridi

2

1 reference

10 August 2017

Muhammad Hassan

3

1 reference

10 August 2017

Mohammad Ali Sadiq

4

1 reference

10 August 2017

Yasir J Sepah

5

1 reference

10 August 2017

Diana V Do

6

1 reference

10 August 2017

Quan Dong Nguyen

7

1 reference

10 August 2017

publication date

1 October 2015

1 reference

10 August 2017

published in

Current diabetes report

1 reference

10 August 2017

volume

15

1 reference

10 August 2017

issue

10

1 reference

10 August 2017

page(s)

75

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-015-0652-z

10 August 2017

exact match

0 references

cites work

Causes of vision loss worldwide, 1990-2010: a systematic analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Anti-vascular endothelial growth factor therapy for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Overview of epidemiologic studies of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Diabetic macular edema: Current management 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Association of vitreous inflammatory factors with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Intravitreal aflibercept for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Advances in ocular drug delivery: emphasis on the posterior segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Recent developments in laser treatment of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

The short-term efficacy of subthreshold Micropulse yellow (577-nm) laser photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561-577-nm) direct photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Subthreshold micropulse diode laser and double frequency neodymium: YAG laser in treatment of diabetic macular edema: a prospective, randomized study using multifocal electroretinography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

NAVILAS Laser System Focal Laser Treatment for Diabetic Macular Edema - One Year Results of a Case Series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Localization of vascular adhesion protein-1 (VAP-1) in the human eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Soluble vascular adhesion protein-1 accumulates in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Von Willebrand Factor (VIII R: Ag), Fibronectin, and Insulin-like Growth Factors I and II in Diabetic Retinopathy and Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Pregnancy-induced increase in circulating IGF-I is associated with progression of diabetic retinopathy in women with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Role of interleukin-1beta in the pathogenesis of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Intraocular soluble intracellular adhesion molecule-1 correlates with subretinal fluid height of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Association of monocyte chemoattractant protein-1 (MCP-1)2518A/G polymorphism with proliferative diabetic retinopathy in northern Chinese type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Association of monocyte chemoattractant protein-1 (MCP-1) 2518A/G polymorphism with proliferative diabetic retinopathy in Korean type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Genetic control of susceptibility in clinical and experimental uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

New treatment options for noninfectious uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Subconjunctival sirolimus in the treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Novel targets against retinal angiogenesis in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Adaptor regulation of LFA-1 signaling in T lymphocyte migration: Potential druggable targets for immunotherapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Evidence underlying the clinical management of diabetic macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Endothelial progenitor cells in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Gene therapy for retinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Vector platforms for gene therapy of inherited retinopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Diabetic retinopathy is associated with oxidative stress and mitigation of gene expression of antioxidant enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Diabetic macular edema: current and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Intravitreal injection of ranibizumab and CTGF shRNA improves retinal gene expression and microvessel ultrastructure in a rodent model of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

MicroRNAs: potential mediators and biomarkers of diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Topical Dexamethasone-Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0652-Z

Functional Characterization of AAV-Expressed Recombinant Anti-VEGF Single-Chain Variable Fragments In Vitro

21 January 2018

1 reference

12 December 2020

Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser

1 reference

12 December 2020

Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology.

1 reference

12 December 2020

Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets

1 reference

12 December 2020

The epidemiology of diabetes mellitus and diabetic retinopathy

1 reference

12 December 2020

Role of microRNAs in the modulation of diabetic retinopathy

1 reference

12 December 2020

Emerging therapies for noninfectious uveitis: what may be coming to the clinics

1 reference

12 December 2020

Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery

1 reference

12 December 2020

SUBTHRESHOLD MICROPULSE YELLOW LASER VERSUS SUBTHRESHOLD MICROPULSE INFRARED LASER IN CENTER-INVOLVING DIABETIC MACULAR EDEMA: Morphologic and Functional Safety.

1 reference

12 December 2020

A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy

1 reference

12 December 2020

Cytokines in the vitreous of patients with proliferative diabetic retinopathy

1 reference

12 December 2020

Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics

1 reference

12 December 2020

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

1 reference

12 December 2020

Blockade of vascular adhesion protein-1 attenuates choroidal neovascularization

1 reference

12 December 2020

10.1007/S11892-015-0652-Z

Identifiers

DOI

1 reference

10 August 2017

1 reference